Trulicity, a GLP-1 analog class diabetes treatment, once again set the record for highest sales. However, it is unclear whether this upward trend will continue in the second half. This is because it is said that some disruptions have occurred in domestic supply due to a shortage of global distribution supplies. Ozempic and Rybelsus, which are considered strong opponents, are waiting for release. In the pharmaceutical industry, if the two drugs are added in earnest, it is expected that the diabetes treatment market, which is dominated by Trulicity, will fluctuate greatly. According to IQVIA, a pharmaceutical market research institute, on the 26th, Trulicity's sales in the second quarter were 18 billion won. Compared t